Detection of a therapeutic response early in the course of cancer treatment, before tumor growth delay or regression, is not currently possible in experimental models or clinical medicine. New interim measures of therapeutic response would be particularly useful in the development of cancer chemosensitization gene therapy by facilitating optimization of gene transfer protocols and prodrug dosing schedules. Diffusion MRI is a sensitive technique producing quantitative and noninvasive images of the apparent mobility of water within a tissue. We investigated the utility of diffusion MRI for detecting early changes associated with a refined cytosine deaminase (CD)/5-fluorocytosine (5FC) chemosensitization
Introduction
In clinical oncology and experimental therapeutics, changes in tumor growth rate or volume are usually the first indication of treatment success. These changes occur late in the course of therapy. The discovery of an earlier indicator of treatment response would be of great value for experimental and clinical trials, particularly of promising, multi-stage interventions such as gene therapy. Chemosensitization gene therapy attempts to overcome the dose-limiting systemic toxicity of chemotherapy by introducing into tumor cells, genes encoding enzymes which convert low-toxicity prodrugs into potent cytotoxic agents. The success of this approach depends on adequate transgene expression and efficient prodrug delivery. Non-invasive assays allowing early characterization of the cellular response to chemosensitization gene therapy could facilitate the development and optimization of gene transfer protocols and prodrug dosing schedules. Such an early surrogate marker of therapeutic outcome could also assist tailoring therapies to individual patients.
Clearly molecular and cellular changes precede macroscopic changes in tumor size and growth. The diffusion of water in tissue is strongly affected by the viscosity of and membrane permeability between intra-and extracellular compartments, active transport and flow, and directionality of structures that impede or enhance mobility. As cells are damaged and killed by therapeutic interventions, the integrity of cell membranes may be compromised and the fractional volume of the interstitial space may increase due to apoptotic body formation and cell loss. Damage to tissue microvasculature may also lead to vasogenic edema thereby reducing the viscosity of the interstitial fluid and increasing the volume of extracellular water. These changes are expected to increase the mobility of water in the damaged tissue. The diffusibility of tissue water in vivo can be accurately and non-invasively quantified as an apparent diffusion coefficient (ADC) by using diffusion MRI. In diffusion imaging, the MR signal intensity is made dependent on water mobility by application of additional pulsed magnetic field gradients to the MR sequence.
1 Individual spins accumulate a phase shift proportional to their spatial position in the gradient field. After waiting a given evolution time for spins to diffuse, an inverse pulse is applied to refocus stationary spins completely, while the mobile spins are refocused incompletely. Thus, the paired gradient pulses attenuate signal in proportion to local tissue water mobility. Quantitative measurements of diffusion as an ADC are obtained by measuring signal attenuation as a function of varying gradient strength and evolution time. Recent work has demonstrated that diffusion MRI is highly sensitive to microscopic changes in tissue struc-ture and physiology. 2, 3 We and others have previously shown that diffusion MRI detects changes in water diffusion in animal tumor models following chemotherapy. [4] [5] [6] [7] [8] [9] [10] These changes preceded changes in tumor growth kinetics and tumor regression.
In this study, we have applied diffusion MRI to evaluate the response of orthotopic 9L gliomas to a refined cytosine deaminase (CD) chemosensitization gene therapy paradigm. 5-Fluorocytosine (5FC) was first identified in a 1957 search for novel anti-neoplastic agents, 11 however, it has only found clinical use as an antifungal drug. 5FC itself does not elicit cytotoxicity, and its antimycotic efficacy depends on the ability of the microbial enzyme CD to convert 5FC to the antimetabolite 5-fluorouracil (5FU). CD is not found in mammals, therefore 5FC has a favorable therapeutic index. The cloning of microbial CDs, coupled with advances in gene transfer technology, have created a new role for flucytosine in cancer therapy. By expressing the CD gene specifically in tumor cells, and administering water-soluble, low-toxicity 5FC systemically, 5FU can be produced in the tumor itself. The resulting 'localized' 5FU chemotherapy may avoid the toxicity associated with systemic 5FU therapy and may improve outcomes by achieving higher intratumoral 5FU concentrations.
Although 5FU is predominantly used in the management of gastrointestinal malignancies, CD and other 'chemosensitization' gene therapy strategies are particularly suited to the treatment of glioma. Unlike other solid malignancies, gliomas rarely metastasize making local control of primary tumor burden the focus of therapy. This facilitates tumor-specific targeting of therapeutic genes by direct stereotactic injection, even when the tumor is not surgically resectable. The normal central nervous system (CNS) tissues which surround gliomas are mitotically inactive; thus the therapeutic index for proliferating cell-selective cytotoxic agents may be improved by local production of the agent within the CNS. The immune-privileged status of the CNS may limit the host-response to the foreign gene products and viral vectors used in gene therapy.
CD gene therapy offers a number of potential advantages over other chemosensitization approaches. First, the produced 5FU is not cell-cycle stage-specific. Second, 5FU freely diffuses across cell membranes, which may improve killing of untransduced 'bystander' cells. Such bystander effect killing is essential for successful gene therapy because of the inefficiency of currently available in vivo gene transfer methodologies. The 5FC prodrug is also membrane permeable, has a high bioavailability, and penetrates the blood-brain barrier and cerebrospinal fluid well. 12, 13 5FU is also a potent radiosensitizing agent 14 and has been shown to have therapeutic activity alone and in combination in orthotopic rodent glioma models. 15, 16 A number of studies have reported growth inhibitory activity of CD gene therapy in glioma cell lines. [17] [18] [19] [20] [21] [22] In each of these studies, the E. coli CD (bCD) gene was used due to the ready availability of its cDNA. In vivo activity has been observed following treatment of subcutaneous tumors derived from glioma cells transduced with bCD before implantation, [18] [19] [20] [21] [22] and in one orthotopic model using adenoviral transduction. 17 The bCD gene was used in these studies because of its ready availability, however, yCD deaminates 5FC much more efficiently than bCD. The cDNA for Sacchromyces cerevisiae was recently cloned, 23, 24 and we have demonstrated that yCD significantly improves the efficacy of CD gene therapy in human colorectal carcinoma xenografts. 25 This was attributed to the more favorable K m and V max of yCD for 5FC, which we showed to be 22-fold lower and six-fold higher than those of bCD, respectively.
The results of this study indicate that yCD has the strong potential to enhance the therapeutic outcome of chemosensitization gene therapy for glioma, and that diffusion MRI may provide an early indication of the tumor response to yCD/5FC treatment.
Results
To demonstrate the therapeutic superiority of yCD over bCD in 9L cells, matched retroviral vectors encoding yCD and bCD, respectively, were used at equivalent titers to infect 9L cells. Western blots of cell extracts obtained from the retrovirally transduced cells demonstrated that the transduced cells expressed the expected proteins (data not shown). The cytotoxicity of 5FC against the retrovirally transduced populations was evaluated using the SRB growth inhibition assay. As shown in Figure 1 , 9L cells transduced with yCD retrovirus are 23.8-fold more sensitive to 5FC exposure in vitro than cells transduced with bCD retrovirus with IC 50 s for 5FC of 12.6 ± 0.5 m and 0.3 ± 0.1 mm, respectively. Control cells infected with LacZ-encoding retrovirus were resistant to 5FC exposure at concentrations greater than 10 mm, precluding determination of an IC 50 value (data not shown).
Clonal lines stably expressing yCD from a CMV promoter were selected as G418-resistant clones isolated by limiting dilution of retrovirally transduced 9L cell pools. The clones with the highest levels of CD expression were selected by cytotoxicity assays with 5FC and Western blotting. The sensitivity of the most sensitive cell line (9LyCD) to 5-FC as assessed by SRB assay was similar to that seen for the pooled retrovirally transduced populations (data not shown). To verify that 9LyCD cells possessed cytosine deaminase activity, cell extracts were prepared, 30 g of which were used in a cytosine deaminase activity assay. Approximately 70% of the [6- 3 H]5FC substrate was converted to 5FU in the presence of 9LyCD extract, while only 2% of the H]5FC was converted to 5FU when extract from parental 9L cells was used.
To assess whether increased tumor diffusion is a response associated with successful yCD/5FC gene therapy, serial ADC maps of rat brains with orthotopic 9L gliomas derived from the stably transduced, clonal 9LyCD line were acquired every other day over the course of the experiment beginning 10 days after tumor cell implantation. Representative ADC maps of a yCDexpressing glioma in a representative rat treated with 5FC (250 mg/kg, i.p., daily for 20 days) over the course of the experiment are shown in Figure 2A . 5FC treatment began 16 days after tumor cell implantation; this day is marked as day 0 in Figure 2A . A qualitative elevation in tumor diffusion was clearly evident by the 8th day after initiating 5FC therapy by the increased intensity of the tumor. The mobility of tumor water remained elevated throughout tumor regression. Similar, serial images of a representative control animal are shown in Figure 2B . The saline-treated 9LyCD tumors grew exponentially throughout the experiment. Note that there was no homogeneous increase in tumor water mobility over the course of the study, however, at the later time points necrotic regions at the center of the tumor demonstrate increased water mobility.
A more quantitative assessment of tumor water mobility can be obtained by examining histograms of tumor pixel ADC values obtained from image sets. Aggregate histograms for the treated and control groups are shown in Figure 3a and b, respectively. These histograms represent the mean number of pixels with a given ADC value over the population of animals studied. The distribution of ADC values in treated tumor began to shift to the right only 6 days after beginning 5FC treatment. The areas under the curve are directly proportional to mean tumor volume, and the beginning of the rightward shift of the distribution was coincident with slowed tumor growth. Note that there is recurrent tumor visible Gene Therapy in the late time-point histograms in the treated group (Figure 3a) . Recurrent tumor was only observed in the one animal that relaspsed following discontinuation of 5FC administration. The recurrent tumor demonstrated low water diffusibility, with an ADC profile similar to that of pre-treatment tumors.
Comparison of ADC histograms in treated and control animals demonstrated that the increased diffusion observed in yCD/5FC-treated tumors is treatment-associated. Mean tumor diffusion in the control animals did not change (Figure 3b) . However, when control tumors became large, regions of high diffusion were observed. These areas corresponded to regions of central necrosis observed in the ADC images. Pixels with low diffusion appear to correspond to peritumoral tissue compressed by the expansive untreated tumors. The inset plot in Figure 3b shows the mean whole tumor ADC as a function of time in the treated and control groups. There is a statistically significant difference between the mean ADC of the 5FC-treated and control tumors beginning on the 8th day of drug administration.
To determine if changes in tumor water mobility precede alterations in tumor growth, whole tumor mean ADC values were compared with tumor volumes determined from the T 2 -weighted, low-b images also obtained during the diffusion scanning session. Figure 4 shows such plots from representative 5FC-treated and control animals. Note that 5FC arrested tumor growth approximately 6 days after beginning administration, which was coincident with significant increases in tumor diffusion (Figure 4a ). These changes preceded regression of the tumor volume, which began 16 days after starting 5FC. Mean tumor diffusion remained constant in the 9LyCD tumors treated with saline over the course of the experiment (Figure 4b ).
The efficacy of 5FC treatment for orthotopic yCDexpressing 9L tumors was measured by animal survival. A Kaplan-Meier plot of animal deaths due to tumor burden is shown in Figure 5 . One 5FC-treated animal died due to tumor recurrence. The other treated animals survived longer than 90 days with no indication of intracranial tumor recurrence by MRI or histopathology, at which time the experiment was ended. The mean survival of the control and treated groups was 28.4 ± 2.9 and greater than 54 days, respectively (P = 0.0018, MantelCox logrank test).
Discussion
The present study demonstrates that yCD chemosensitization gene therapy induces changes in the MR-observable diffusibility of water within the tumor prior to tumor growth arrest and regression. These initial results indicated that tumor water diffusion remains elevated throughout the course of 5FC administration and tumor regression. It appears that an elevated ADC is associated with active destruction of tumor tissue, as the ADC profile of the single recurrent tumor was similar to that of the primary tumor before any therapeutic intervention.
These results parallel earlier reports on the diffusional behavior of tumor water following therapy. We previously observed that the ADC of tumor water in orthotopic 9L gliomas increased 55% by the 6th day after treatment with high-dose BCNU chemotherapy. 6 These changes also occurred before tumor growth arrest and regression. Other groups have reported similar phenomena in a number of animal models. Zhao et al 5 observed dose-dependent changes in whole tumor ADC in a subcutaneous mouse fibrosarcoma model after cyclophosphamide therapy. More recently, diffusion increases were reported in MCF-7/S, but not drug-resistant MCF-7/D40, breast carcinoma xenografts following taxol chemotherapy. 10 Recent studies using MCF-7 breast cancer xenografts demonstrated a direct correlation between tumor cell apoptosis and increases in ADC values following treatment with ionizing radiation and TRAIL.
26 BT4C rat gliomas pre-transduced with HSVtk also exhibit increased tumor water diffusion after treatment with ganciclovir. 8, 9 In light of these other studies, our results suggest that increases in tumor water diffusion may be a universal response of neoplasms to successful therapeutic intervention.
The ADC mapping techniques and serial analysis of diffusion histograms employed in this study offer significant advantages over the region-of-interest diffusion measurements that have previously been made of experimental tumor models during anti-cancer treatment. The ADC maps generated in this study reveal that there is regional heterogeneity in the diffusion response, even in tumors uniformly expressing the yCD transgene. The assessment of intra-tumoral heterogeneity will be particularly important in true yCD and other gene therapy experiments and clinical trials by allowing investigators to correlate regions of tumor cell death with sites of stereotactic delivery of vectors carrying therapeutic transgenes. This approach will be even more powerful when combined with interim measures of transgene expression, such as non-invasive, 19 F MR spectroscopic measurements of yCD activity which we have recently reported. 27 The increased diffusion observed in this study could be due to a number of changes in the microstructure of the treated tumor. The water diffusion signal in tumors appears to be predominated by the diffusion of interstitial water. 8, 28 Thus, the increases in measured ADC values could represent an increased ratio of extra-to intra-cellular space due to apoptotic body formation and/or generally decreased cellularity. Decreased viscosity of the extracellular fluid as a function of vasogenic edema and endothelial cell damage may also contribute to the observed changes in tumor water diffusion. Determining the relative roles of these processes requires further investigation.
This study also demonstrates the efficacy of yCD gene therapy in an orthotopic glioma model. Although there was one animal that developed a recurrent tumor, there was no MRI or histological evidence of residual intracranial tumor in the other animals. In contrast, no complete regressions were observed when subcutaneous tumors in nude mice derived from bCD-expressing 9L cells were treated with 5FC at 500 mg/kg i.p for 28 days. 22 Dong et al 17 treated orthotopically implanted 9L tumors with adenovirus carrying bCD followed by 5FC administration. Although they observed long-term survivors (Ͼ130 days), they performed viral transduction only 4 days after cell implantation and began 5FC treatment 2 days later, and thus were not treating large established tumors as was the case in the present experiment.
The large diffusion responses observed in this study suggest that diffusion MRI may have the sensitivity to detect the less robust responses which may be obtained following in vivo transduction with a chemosensitizing gene like yCD or after fractionated-dose radiation or chemotherapy. In this regard, we have observed diffusion responses in 9L gliomas following a single 6.7 mg/kg dose of BCNU which elicited a 0.2 log-cell kill (unpublished observations). The full prognostic ability of diffusion MRI remains unclear and mandates additional study. The sensitivity of diffusion MRI to changes in tissue structure should benefit experimental therapeutics by providing new tools for analyzing therapeutic outcomes in laboratory models and clinical trials. This property of diffusion imaging gives it the potential for early assessment treatment response in individual patients. Such early, reliable prognostic information may help physicians tailor treatment plans to individual patients and would allow alternative therapies to be attempted in a more timely fashion if a tumor appears resistant.
Materials and methods
Vectors and cell lines Rat 9L glioma cells were obtained from the Brain Tumor Research Center at the University of California at San Francisco and grown as monolayers in minimal essential medium supplemented with 10% fetal calf serum, 100 IU/ml penicillin and 100 mg/ml streptomycin, and 2 mm l-glutamine at 37°C in a 95%/5% air/CO 2 atmosphere. 9LyCD and 9LbCD cell lines, stably expressing yCD and bCD, respectively, were generated by retroviral infection using the LZR/Phoenix system, as previously described. 25 Cells were replated 24 h after infection and
Gene Therapy cell lines arising from individual colonies were CD expression by Western blot and 5FC sensitivity.
In vitro cytotoxicity assays Growth inhibition was evaluated using the sulforhodamine B assay (SRB) as previously described. 29 Briefly, 12 to 18 h before infection, 9L cells were seeded at a density of 1000 cells/cm 2 in 96-well plates. Twenty-four hours after infection with 2 × 10 6 cfu/ml of bCD or yCD retrovirus, the cells were treated with medium supplemented with vehicle (PBS) or 5-FC (Sigma, St Louis, MO, USA). Cells were treated for 72 h, and were then allowed to grow until untreated cells reached confluence, at which time the cells were fixed and stained. A microtiter plate reader was used to measure the absorbance at 490 nm (V max , Molecular Devices, Sunnyvale, CA, USA). Data plotted represent the mean and standard deviation of eight replicate wells.
Animal model
Intracerebral 9L tumors stably and uniformly expressing yCD were induced in male Fischer 344 rats weighing between 125 and 150 g as previously described. 30 Briefly, 9LyCD cells (10 5 ) were implanted in the right forebrain at a depth of 3 mm through a 1 mm burr hole. The surgical field was cleaned with 70% ethanol and the burr hole was filled with bone wax to prevent extracerebral extension of the tumor. 5FC treatment was initiated 14 days after tumor cell implantation. 5FC was given as a solution in normal saline by i.p. injection at a dose of 250 mg/kg once per day for 20 days. Control 9LyCD animals received vehicle-only injections.
CD enzyme assay
Cytosine deaminase activity in 9LyCD cells was quantified by the percentage of conversion of [6- 3 H] 5-FC as previously described. 25 In brief, cell extracts were prepared as described, and incubated in the presence of radiolabeled 5FC for 2 h at 37°C. The produced 5FU was isolated using an SCX Bond column (Varian, Harbor City, CA, USA) and counted to determine the percentage conversion.
Diffusion magnetic resonance imaging
Imaging was performed every other day beginning 10 days after tumor cell implantation on a Varian Unity Inova system equipped with a 7.0 tesla, 18.3 cm horizontal bore magnet and a quadrature rat head coil (USA Instruments, Aurora, OH, USA). For MRI examination, rats were anesthetized with an isofluorane/air mixture and maintained at 37°C inside the magnet using a heated, thermostated circulating water bath. A single-slice sagittal spin-echo sequence was used to confirm proper animal positioning and to prescribe subsequent imaging. An isotropic, diffusion-weighted sequence 31 was employed with two interleaved b-factors (⌬b = 1148 s/mm 2 ) and the following acquisition parameters: TR/TE = 3500/60 ms, 128 × 128 matrix, and a 3 cm FOV. It has been shown that there are no significant differences in apparent diffusion coefficient (ADC) values measured by faster twopoint diffusion techniques versus six b-factor methods. 32 Thirteen 1-mm thick slices separated by a 0.2-mm gap were used to cover the whole rat brain. The z-gradient first moment was set at zero to reduce the dominant source of motion artifact. To reduce the motion artifact further, a 32-point navigator echo was prepended to each phase-encode echo. The phase deviation of each navigator echo relative to their mean was subtracted from the respective image echoes before the phase-encode Fourier transform. The low b-factor images were essentially T 2 -weighted to allow tumor volume measurements, as previously described. 30 Images were acquired before treatment and at 2-day intervals thereafter. Isotropic ADC maps were calculated for each image set and ADC pixel value histograms were generated from tumor ROIs combined across slices.
